EGFR and colorectal cancer: The CO-17 study, which compared treatment with cetuximab and best supportive care (BSC) to BSC alone in patients with metastatic EGFR-positive colorectal cancer, revealed that EREG expression levels were positively correlated with cetuximab treatment efficacy [29].